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Summary
Candida albicans is a major human fungal patho-
gen causing mucosal and deep tissue infections of
which the majority is associated with biofilm for-
mation on medical implants. Biofilms have a huge
impact on public health, as fungal biofilms are
highly resistant against most antimycotics. Animal
models of biofilm formation are indispensable for
improving our understanding of biofilm develop-
ment inside the host, their antifungal resistance
and their interaction with the host immune defence
system. In currently used models, evaluation of
biofilm development or the efficacy of antifungal
treatment is limited to ex vivo analyses, requiring
host sacrifice, which excludes longitudinal moni-
toring of dynamic processes during biofilm forma-
tion in the live host. In this study, we have
demonstrated for the first time that non-invasive,
dynamic imaging and quantification of in vitro and
in vivo C. albicans biofilm formation including
morphogenesis from the yeast to hyphae state is
feasible by using growth-phase dependent biolu-
minescent C. albicans strains in a subcutaneous
catheter model in rodents. We have shown the
defect in biofilm formation of a bioluminescent
bcr1 mutant strain. This approach has immediate
applications for the screening and validation of
antimycotics under in vivo conditions, for studying
host–biofilm interactions in different transgenic
mouse models and for testing the virulence of
luminescent C. albicans mutants, hereby contri-
buting to a better understanding of the pathogen-
esis of biofilm-associated yeast infections.
Introduction
Fungal infections have become increasingly important for
environmental, animal and human health (Fisher et al.,
2012). In humans, fungal infections caused by yeasts
(e.g. Candida albicans, Cryptococcus neoformans) and
molds (e.g. Aspergillus fumigatus) have emerged over the
past two decades and become more and more significant
in clinical practice (Nucci and Marr, 2005; Warnock, 2006;
Chen et al., 2010). C. albicans is part of the commensal
flora of the digestive system and vaginal tract of healthy
individuals, but it is also an opportunistic pathogen under
certain conditions. C. albicans is the most often isolated
species in fungal infections (Wisplinghoff et al., 2004;
Enoch et al., 2006; Kim and Sudbery, 2011; Pemán and
Salavert, 2012). When the host defences are weakened,
infections can occur that range from superficial to sys-
temic and even life threatening candidiasis (Wisplinghoff
et al., 2004; Kim and Sudbery, 2011). The emergence of
fungal diseases is related to an increase in severely ill
or immune compromised patients over the past three
decades (Eggimann et al., 2003a,b; Nucci and Marr,
2005; Giri and Kindo, 2012). The growing use of
implanted medical devices is another reason why the
incidence of fungal infections has steadily increased, as
many of these infections are emerging from biofilms
formed on medical implants (Nucci and Marr, 2005; Pfaller
and Diekema, 2010; Giri and Kindo, 2012). They are a
major problem in hospitals (Douglas, 2003) as cells in
such biofilms are difficult to treat since they are often
tolerant to the classical antifungal drugs (Hawser and
Douglas, 1995; Lewis et al., 2002). A major challenge in
Candida biofilm research is the development of suitable
models that account for host factors at different infection
sites and that allow to evaluate the potential and efficacy
of novel antifungal treatment strategies under in vivo
conditions (Nett and Andes, 2006).
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cellular microbiology
Among others, an intravenous catheter model (Andes
et al., 2004) and a subcutaneous catheter model
(Rˇ icˇicová et al., 2010) allow in vivo Candida biofilm
research and have greatly facilitated antifungal testing in
small animals (Schinabeck et al., 2004; Kucharíková
et al., 2010; 2013). These models have in common that
fungal load in biofilms is analysed post mortem, requiring
host sacrifice and enumeration of microorganisms from
individual biofilms to evaluate the efficacy of antifungal
treatment. Also for studying biofilms formed under in vivo
conditions, evaluation of biofilm properties (architecture,
morphology) are limited to ex vivo techniques such as
microscopic analysis. This approach requires the use of
many animals, is labour intensive and only provides one
time point per animal and therefore does not enable moni-
toring of the true time-course of biofilm formation and
pathogenesis in vivo.
Different imaging modalities are available that enable
non-invasive and repeated imaging of targeted cells in
living organisms, but especially bioluminescence imaging
(BLI) has emerged as a powerful new method to analyse
infectious diseases in animal models and microbial viabil-
ity in particular (Hutchens and Luker, 2007). BLI is based
on the detection of visible light (photons) that is produced
by an enzymatic oxidation of a substrate, catalysed by
luciferase enzymes. It is one of the few imaging methods
that can non-invasively quantify cell viability. BLI provides
the opportunity to serially and quantitatively monitor infec-
tion and microbial load in a single host over time (Sjolinder
and Jonsson, 2007). Although BLI is well established for
imaging different (microbial) cell populations (Contag
et al., 1995; Hutchens and Luker, 2007), it is particularly
challenging for fungal pathogens (d’Enfert et al., 2010;
Brock, 2012). Unlike bacteria that can be genetically engi-
neered to express all necessary components for the bio-
luminescence reaction from the lux operon, fungal and
other eukaryotic cells depend on external substrate
administration for the bioluminescence reaction. Because
of their cell wall, the diffusion of the necessary substrate
for the light producing reaction is limited, hampering
detection of the resulting weak BLI signal in vivo, espe-
cially from deeper infection sites (Doyle et al., 2006). The
permeability of hyphal cells to the firefly luciferase sub-
strate luciferin is even more limited resulting in the inability
to quantifiable image them during infection (Doyle et al.,
2006). This was an important obstacle given the impor-
tance of the yeast-to-hyphae transition in C. albicans viru-
lence (Biswas et al., 2007). A Gaussia princeps luciferase
(gLuc) enzyme that is located extracellularly has made
BLI of hyphal cells possible, thereby showing substantial
improvement in the use of BLI as a tool to monitor super-
ficial C. albicans infections (Enjalbert et al., 2009). Addi-
tionally, yeast and hyphal cell growth could each be
visualized in vitro by tagging luciferase to cell wall proteins
that are specifically expressed in either of these morpho-
logical forms (Enjalbert et al., 2009). However, the possi-
bility to image the time-course of biofilm formation and
morphology transitions during biofilm growth in vitro and
in vivo has not been investigated before. As imaging
biofilms in catheters inside the animal poses extra chal-
lenges due to light scattering, we explored the feasibility
to non-invasively image C. albicans biofilm development
in vivo by using BLI in a subcutaneous catheter model.
Furthermore, as the yeast-to-hyphae transition is a key
factor involved in C. albicans biofilm formation and patho-
genicity, we investigated if the time-course of C. albicans
biofilm morphogenesis under in vitro and in vivo condi-
tions can be monitored with BLI. We also used BLI to
monitor the effect on biofilm formation of the C. albicans
Bcr1 gene which plays a central role in in vitro and in vivo
substrate adhesion and biofilm formation, by using a bio-
luminescent BCR1 deletion strain.
Results
Minimizing background signal for BLI
Catheters are often made radio-opaque to enable the
assessment of the catheter position inside the body. For
example, barium sulfate filler is added to make the cath-
eter visible under fluoroscopy and on X-ray images.
However, barium sulfate phosphoresces. Therefore, we
tested different intravenous catheters for background
luminescence when imaged with BLI and found two out of
three to be highly phosphorescent in vitro (Fig. 1 panel A
and Fig. S1), which is a confounding factor for evaluating
the specific bioluminescent signal and signal kinetics from
gLuc-expressing C. albicans biofilms in vitro.
To assess the relevance of this phosphorescence back-
ground signal from the catheters for BLI in vivo, catheters
containing biofilms of ACTgLuc-expressing C. albicans
and empty catheter pieces were implanted subcutane-
ously. After catheter implantation and after 2 and 6 days
of biofilm maturation, the mice were imaged by BLI.
Images acquired sequentially before and after opening
the scanner door and with or without addition of coelen-
terazine (CTZ) – the substrate used for the biolumines-
cence reaction – were compared. At all time points, we
detected a clearly visible signal from empty implanted
Arrow catheters without addition of CTZ (Fig. 1 panels B
and C). This signal increased significantly every time the
animals were exposed to light (i.e. when opening the
scanner door), indicating that the detected signal origi-
nated from phosphorescence of the catheter pieces.
Next, we opened the door and added CTZ to the catheters
and compared the specific BLI signal from biofilms of
ACTgLuc-expressing cells with light emanating from
empty catheters. Unlike for the empty catheters, the BLI
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signal intensity from catheters containing ACTgLuc-
expressing cells increased significantly above the phos-
phorescence signal upon CTZ addition (Fig. 1 panels B
and C). However, the additional increase in luminescence
upon CTZ addition was relatively small compared with
the increase in catheter phosphorescence upon opening
of the scanner door. Performing the same in vivo experi-
ment using non-phosphorescent catheters (Certofix),
Fig. 1. Phosphorescence of different common catheter types.
A. Three different brands of triple lumen catheters (Arrow, Edwards Swan-Ganz, BBraun Certofix) were cut in 1 cm long pieces and 60
consecutive 20 s-frames were acquired with the BLI camera and compared with the background signal (see Fig. S1). Before the sequence
and after the 30th imaging frame, the catheters were exposed to light by opening-closing of the scanner door (arrows). Edwards Swan-Ganz
and Arrow catheter fragments clearly showed phosphorescence signal after exposure to daylight, decaying over time. For the BBraun Certofix
catheter, no phosphorescence was detected and its signal intensity was equal to background.
B and D. Quantification of the in vivo luminescence signal from empty catheter pieces and catheter pieces carrying biofilms formed by
SKCA23-ACTgLuc C. albicans cells, acquired at 2 days after catheter implantation, using Arrow (B) and Certofix (E) catheters.
C and E. In vivo BLI images from a representative mouse at the 2 days’ time point are shown, acquired after keeping the scanner door
closed, after opening of the scanner door and after opening of the scanner door and CTZ administration, using Arrow (C) and Certofix
(E) catheters (Error bars represent SD of triplicate samples; *P < 0.05, **P < 0.005, ***P < 0.0005).
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no phosphorescent background signal could be detected
after exposing the animals to light (Fig. 1 panel E). A
significant BLI signal above background could clearly be
visualized and quantified only upon addition of CTZ to
catheters containing biofilms formed by ACTgLuc-
expressing Candida cells (Fig. 1 panels D and E). There-
fore, and to avoid complications in signal analysis due to
different kinetics of the phosphorescence and ACTgLuc-
induced BLI signals, we have used non-phosphorescent
catheters (Certofix) for all further in vitro and in vivo BLI
experiments. Biofilms formed on the non-phosphorescent
catheters showed the same properties regarding biofilm
formation (data not shown) and were therefore com-
parable to biofilms formed on the catheters used in pre-
vious studies (Kucharíková et al., 2010; Rˇ icˇicová et al.,
2010).
BLI of in vitro biofilm formation
CTZ is known to undergo some auto-oxidation in the
presence of oxygen, contributing to a background BLI
signal (Shimomura et al., 1993; Tannous et al., 2005).
Therefore, we determined the minimum number of
ACTgLuc-expressing C. albicans cells in suspension that
resulted in a detectable BLI signal, significantly above the
background signal. A fixed CTZ concentration was added
to empty wells and to 10-fold dilution series of ACTgLuc-
expressing and wild-type (wt) C. albicans cells (Fig. 2,
panel A). The BLI signal intensity measured from 104 or
more ACTgLuc-expressing C. albicans cells was found to
be significantly higher than the background signal origi-
nating from auto-oxidation of CTZ alone or incubated with
non-luminescent wt cells. The specific BLI signal strongly
Fig. 2. BLI of in vitro C. albicans biofilm formation.
A. BLI of 10-fold dilutions of SKCA23-ACTgLuc and SC5314 (wt control) C. albicans cells, and CTZ alone (n = 3). In vitro detectability was
established to be ≥ 104 cells.
B. BLI signal intensity and metabolic activity measurements of biofilms formed by SKCA23-ACTgLuc and SC5314 C. albicans cells on the
bottom of 96-well plates (n = 6).
C. BLI signal and cfu quantification of biofilms formed by SKCA23-ACTgLuc and SC5314 C. albicans cells on the bottom of 24-well plates
(n = 3). A typical BLI image of 2-day-old mature biofilms is shown on the right (n = 3 per strain).
D. Graphs of BLI signal intensity and cfu quantification of biofilms formed by SKCA23-ACTgLuc and SC5314 C. albicans cells in catheter
pieces (n = 6). A typical BLI image of 2-day-old mature biofilms formed on the inside of catheter pieces (n = 6 per strain) is shown on the right
(Error bars indicate SD of replicate samples; *P < 0.05, **P < 0.005, ***P < 0.0005).
118 G. Vande Velde et al.
© 2013 The Authors. Cellular Microbiology published by John Wiley & Sons Ltd, Cellular Microbiology, 16, 115–130
correlated with the amount of ACTgLuc-expressing
C. albicans cells (R2 = 0.998).
To investigate the feasibility of using BLI for imaging
biofilm development, we first evaluated the BLI signal
intensity from C. albicans biofilms formed on the bottom
of polystyrene cell culture plates in vitro. ACTgLuc-
expressing and wt C. albicans cells were allowed to adhere
to the bottom of 96- and 24-well cell culture plates and
incubated for mature biofilms to be formed. BLI was per-
formed after 90 min (period of adhesion) and after 2 and 6
days of mature biofilm formation. At every imaging time
point, the metabolic activity of the biofilm forming cells (in
96-well plates) and colony-forming units (cfu) (in 24-well
plates) were quantified. At all imaging time points, the BLI
signal from ACTgLuc-expressing biofilms formed on
96-well plates was significantly higher than from wt biofilms
(Fig. 2, panel B). Two days after adhesion, the BLI signal
was significantly increased for ACTgLuc-expressing
biofilms, which is consistent with mature biofilm develop-
ment at this stage (Kucharíková et al., 2011). The notice-
able finding that the BLI signal from wt biofilms was also
increased can probably be attributed to the increase of
organic matter in the extracellular matrix, which might
stimulate CTZ auto-oxidation. The BLI signal of 6-day-old
biofilms was decreased, which can be explained by
a limitation in nutrients, which corresponds to the metabolic
activity of the cells in the biofilm measured by
the XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-
Tetrazolium-5-Carboxanilide) assay. Overall, the BLI data
was in agreement with the metabolic activity of the biofilm
forming cells as measured by the XTT reduction assay
(Fig. 2, panel B).
For biofilms formed in 24-well plates, nutrients are less
likely to be a limiting factor for biofilm development com-
pared with biofilms formed in 96-well plates. Indeed, the
BLI signal intensity from biofilms formed by ACTgLuc-
expressing C. albicans as well as from wt cells increased
significantly after 2 and 6 days of mature biofilm formation,
which was corroborated by a significant increase of cfu
over time (Fig. 2, panel C). Importantly, the BLI signal from
ACTgLuc-expressing C. albicans biofilms was at every
imaging time point significantly higher than the background
BLI signal measured from wt C. albicans biofilms, for the
same amount of cfu per biofilm (Fig. 2, panel C).
We next evaluated the BLI signal intensity from biofilms
formed inside polyurethane catheter pieces in vitro.
Similar to the results for biofilms formed on cell culture
plates, the specific BLI signal from ACTgLuc-expressing
biofilms was at every imaging time point significantly
higher than the background BLI signal measured from wt
biofilms. From the period of adhesion (90 min) towards
mature biofilm formation on day 2, the BLI signal
increased significantly for both ACTgLuc-expressing and
wt biofilms (Fig. 2, panel D). From day 2 to day 6 of biofilm
maturation, the BLI signal intensity remained at the same
level. These BLI results were in agreement with the cfu
retrieved from each biofilm that were also significantly
increased on day 2 and remained unchanged by day 6
(Fig. 2, panel D).
Taken together, our data indicate that BLI can be used
as a sensitive tool to monitor in vitro biofilm development
on foreign bodies, including on biofilms formed on the
inside of catheter pieces.
BLI of biofilms formed in vivo
We evaluated the feasibility to non-invasively follow-up in
vivo biofilm development in subcutaneously implanted
catheters with BLI. Hereto, three catheters inoculated with
wt C. albicans cells were implanted on the left side and
three catheters inoculated with ACTgLuc-expressing
C. albicans were implanted on the right side under the
skin of the lower back of mice (n = 12). In vivo biofilm
formation was visualized with repeated BLI starting on the
same day of catheter implantation, and after 2 and 6 days
of mature biofilm formation. Catheter pieces (n = 4 per
C. albicans strain) were handled in parallel with the cath-
eters for implantation, imaged in vitro with BLI and used
for quantification of cfu at the adhesion time point to verify
adhesion of equal numbers of cells on all catheters at the
time of implantation. After catheter implantation (n = 12)
and after 2 days (n = 12), all mice were imaged with BLI.
After the 2 days’ imaging time point, half of them (n = 6)
were sacrificed for catheter explantation and ex vivo
quantification of biomass for validation of the BLI results.
At the 6 days’ imaging time point, the remaining half of the
group (n = 6) was imaged and sacrificed thereafter for
catheter explantation.
At every imaging time point, a significant BLI signal
above background was detected from ACTgLuc-
expressing biofilms formed on the inside of catheters in
vivo, while ACTgLuc-expressing and wt biofilms were
verified to contain the same amount of cfu per biofilm
(Fig. 3, panel A). The BLI signal could clearly be visual-
ized and followed up over time in every individual animal
(Fig. 3, panel B) and was in agreement with the amount of
cfu quantified from the biofilms (Fig. 3, panel A). Interest-
ingly, wt biofilms elicited a significant BLI signal above
background at all time points, as was also observed for
the in vitro biofilm BLI experiments (Fig. 2). However, at
every imaging time point, the BLI signal quantified from
ACTgLuc-expressing biofilms was at least one order of
magnitude (i.e. log10) and significantly higher than the
background signal of wt biofilms, indicating that BLI can
be used for longitudinal monitoring and quantification of in
vivo biofilm development on implanted catheters.
As bioluminescence images represent low-resolution
2D projections overlaid on a planar photographic image,
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individual catheters might not always be clearly visible on
the resulting image. Therefore, signal quantification may
potentially suffer from variability due to implantation depth
and/or incorrect delineation of the catheters. Also, light
absorption due to scar formation or unexpected bleedings
may affect BLI quantification. We have therefore acquired
high-resolution magnetic resonance (MR) images while
the animals were still anesthetized from BLI and fixed to
the same reference frame, i.e. animal holder. Anatomical
details and the position of the catheters as visualized on
the MR images were used for delineation of the region of
interests (ROIs) used for subsequent BLI signal quantifi-
cation (Fig. 3, panel C). In order to explore the potential of
MRI to improve the accuracy of BLI signal quantification,
the BLI signal quantified from correctly positioned ROIs
using prior knowledge from the MR images was compared
with BLI signal intensities quantified from ROIs that were
placed over the focus of the BLI signal spot while varying
the angulation of the ROI. No significant influence from
different angulations of the ROIs could be found (data not
Fig. 3. BLI of in vivo biofilm formation.
A. In vivo BLI signal quantification from biofilms formed by SKCA23-ACTgLuc and SC5314 (wt) C. albicans cells on implanted catheter pieces,
after catheter implantation (90 min, n = 12 mice) and after 2 (n = 12 mice) and 6 days (n = 6 mice) of in vivo biofilm development, compared
with the background (BG) BLI signal from a subcutaneous CTZ injection. The graphs on the right represent cfu quantified from biofilms formed
by SKCA23-ACTgLuc and SC5314 C. albicans cells at the time of implantation (90 min, n = 4 per strain) or explanted from mice after 2 and 6
days (n = 18 per strain) (Error bars indicate SD of replicate samples; *P < 0.05, **P < 0.005, ***P < 0.0005).
B. In vivo BLI images from one representative (i.e. showing average BLI signal) mouse imaged at three different time points after catheter
implantation are shown.
C. in parallel with BLI, MR images were acquired to visualize the exact three-dimensional catheter position for verifying correct ROI placement
and quantification of the BLI signal. Two adjacent slices from a typical MRI dataset overlaid with ROIs for photon flux quantification (yellow
rectangles) are shown on the left with the corresponding BLI image on the right.
D. SEM of 6-day-old mature biofilms formed by C. albicans SC5314 (wt, on the left) and SKCA23-ACTgLuc (on the right) inside polyurethane
catheter fragments in vivo. After explantation, the catheters were longitudinally cut and fixed before SEM. Magnification of the left panels is
500× (scale bars measure 50 μm). The right panels are 1200× magnifications of the black boxed area (scale bars measure 20 μm).
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shown), which indicates that fine-tuning of the ROI posi-
tion is not a prerequisite for accurate BLI quantification in
animal models of subcutaneously implanted catheters.
For all animals, we confirmed a similar implantation depth
of the catheters and the absence of bleedings or the
formation of major scar tissue between the catheters and
the skin of the animals.
To investigate a possible unwanted effect of ACTgLuc-
transgene expression on the biofilm structure, catheters
carrying biofilms maturing under in vivo conditions
explanted at 6 days after implantation were examined by
scanning electron microscopy (SEM) as described before
(Rˇ icˇicová et al., 2010). It was verified that ACTgLuc-
transgene expression did not alter the in vivo biofilm archi-
tecture (Fig. 3, panel D).
BLI of C. albicans morphogenesis during
biofilm development
In a next step, we investigated whether the expression
of gLuc under control of a morphogenesis-dependent
promoter can be applied for BLI of the C. albicans
yeast-to-hyphae transition during biofilm formation. For
these experiments, we used the CEC971-HWPgLuc
C. albicans strain (Enjalbert et al., 2009), which
expresses gLuc under control of a hyphal promoter that
becomes active when cells undergo yeast-to-hyphae tran-
sition (Staab et al., 1996). As a control, we used a strain
that expresses gLuc under control of the constitutively
active ACT1 promoter, i.e. in both the yeast and hyphal
forms (CEC988-ACTgLuc).
First, we determined the BLI signal of 10-fold dilution
series of CEC988-ACTgLuc, CEC971-HWPgLuc,
DAY185 (wt control) C. albicans cell suspensions and
CTZ alone. The BLI signal intensity from the cells
expressing gLuc under control of the HWP1 promoter was
equal to the background BLI signal from the controls. A
specific BLI signal that correlated with the number of cells
could only be detected for C. albicans expressing gLuc
under control of the ACT1 promoter (R2 = 0.998, Fig. 4,
panel A). These results are in line with C. albicans cells
known to be in the yeast form in serum-free medium
(Sudbery, 2011). Next, we tested whether the transition
from the yeast form to the hyphal form can be monitored
with BLI, which is known to be stimulated by adding serum
to the medium (Sudbery, 2011). We incubated wt,
ACTgLuc- and HWPgLuc-expressing cells with and
without fetal bovine serum (FBS) (10%) in the culture
medium and imaged them after 1.5 h and 4.5 h with BLI.
The relative increase in BLI signal intensity from
HWPgLuc-expressing cells grown in medium compared
with serum-free medium was significantly higher than the
increase in signal intensity measured from wt and
ACTgLuc-expressing cells, both after 1.5 h and 4.5 h of
incubation (Fig. 4, panel B). These results demon-
strate that BLI can be used to quantify hyphal growth
in vitro.
Furthermore, we evaluated whether the hyphal growth
during in vitro biofilm formation in catheter pieces can
be followed with BLI. Catheters were incubated with
ACTgLuc- (n = 12) or HWPgLuc-expressing C. albicans
(n = 12) in medium containing FBS, which is known to
stimulate yeast-to-hyphae transition (Sudbery, 2011).
After 90 min, 2 days, 6 days and 9 days of biofilm growth,
three catheters of each strain were imaged with BLI,
followed by cfu quantification. At each time point, the
number of cfu recovered from biofilms formed by each
strain was equal, confirming that differences in BLI signal
intensity between the strains were not due to differences
in the amount of biofilm forming cells (Fig. 4, panel C).
After 90 min of C. albicans cell adhesion on the catheters,
a significantly lower BLI signal intensity was detected from
HWPgLuc-expressing C. albicans cells compared with
ACTgLuc-expressing cells, corresponding to the lower
numbers of C. albicans hyphal cells compared with yeast
cells, characteristic at this stage (Blankenship and
Mitchell, 2006). After 2 days of biofilm growth, the BLI
signal intensities from both yeast as well as hyphal cells
showed to be significantly increased due to biofilm prolif-
eration, whereas after 6 days they remained at the same
levels when the mature biofilm is maintained. That
HWPgLuc-expressing C. albicans cells showed a more
pronounced BLI signal intensity increase during the first
days of biofilm formation relative to ACTgLuc-expressing
cells corresponds to hyphal growth in addition to cell
proliferation during mature biofilm development. After 9
days of in vitro biofilm growth, the BLI signal intensity from
both ACTgLuc- and HWPgLuc-expressing biofilms has
decreased, which is in agreement with the lower cell
numbers (cfu) recovered from the catheters.
In order to demonstrate the potential of BLI to non-
destructively determine the yeast-to-hyphal cell ratio, we
imaged HWPgLuc-expressing C. albicans cells that were
either in the yeast or hyphal stage, or as mixtures at
different ratios of yeast to hyphal cells. The percentage of
yeast to hyphal cells could be calculated from the biolu-
minescence signal of the samples (Fig. S2), demonstrat-
ing that the yeast-to-hyphae ratio can be determined by
using BLI.
To verify whether BLI can be used as a technique
to non-invasively follow up on hyphal growth in vivo,
catheters inoculated with ACTgLuc- or HWPgLuc-
expressing C. albicans were implanted on the back of
mice (n = 6). All mice were repeatedly monitored with BLI
on the same day of catheter implantation (adhesion of
C. albicans cells to the catheters) and after 2, 6 and 9
days of biofilm maturation. After catheter implantation, all
mice exhibited a significantly lower BLI signal intensity
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from HWPgLuc-inoculated catheters (Fig. 4, panel D and
E). After two days of biofilm maturation, there was a more
pronounced and significant increase in the BLI signal for
HWPgLuc-expressing C. albicans biofilms compared with
ACTgLuc-expressing biofilms, indicating hyphal growth.
When the biofilm matures further, the BLI signal
from ACTgLuc-expressing biofilms showed a decrease
whereas the BLI signal from HWPgLuc-expressing
biofilms remained largely unchanged. This may point to
the mainly hyphal content of biofilms of this age (Nett and
Andes, 2006). After the last imaging time point at day
nine, the mice (n = 6) were sacrificed and cfu were quan-
tified from explanted catheters, confirming that biomass
was comparable among all biofilms (Fig. 4, panel E).
Taken together, the data indicate that BLI can be used to
monitor hyphal growth during in vitro and in vivo biofilm
formation, which is most pronounced during the earliest
stage of biofilm development.
Fig. 4. In vitro and in vivo BLI of C. albicans morphogenesis during in vitro and in vivo biofilm formation.
A. In vitro BLI of 10-fold dilutions of CEC988-ACTgLuc, CEC971-HWPgLuc, DAY185 (wt control) C. albicans cell suspensions in serum-free
medium and CTZ alone.
B. In vitro BLI of the yeast-to hyphae transition of CEC988-ACTgLuc, CEC971-HWPgLuc, DAY185 (wt control) C. albicans cell suspensions
upon incubation for 1.5 h and 4.5 h in serum-containing medium compared with serum-free medium. The data is represented as the relative
increase in BLI signal upon incubation in serum-containing medium relative to the BLI signal from cell suspensions incubated in serum-free
medium (n = 3 per condition and strain).
C. in vitro BLI signal and cfu quantification from biofilms formed by CEC988-ACTgLuc and CEC971-HWPgLuc C. albicans cells on catheter
pieces (n = 3).
D. Representative in vivo BLI image of an average mouse at the same day after catheter implantation.
E. In vivo BLI signal (n = 6 mice) and cfu (n = 18 catheters) quantified from biofilms formed by CEC988-ACTgLuc and CEC971-HWPgLuc
C. albicans in implanted catheter pieces (Error bars indicate SD of replicate samples; *P < 0.05, **P < 0.005, ***P < 0.0005).
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BLI of defective biofilm formation by BCR1
mutant C. albicans
In the next series of experiments, we aimed to use
and validate BLI to identify biofilm-defective mutants.
For these experiments, we used a C. albicans BCR1
knockout strain that was engineered to constitutively
express gLuc on its cell wall in order to non-invasively
image its capacity to adhere to and form biofilms inside
catheters. The bioluminescence emitted by this ACTgLuc-
expressing bcr1−/− strain showed to be directly compara-
ble to the bioluminescence of the ACTgLuc-expressing
strain (SKCA23-ACTgLuc), used as wild type control for
biofilm formation in the following experiments (Fig. S3,
panel A).
First, we used BLI to evaluate the capacity of ACTgLuc-
expressing bcr1−/− C. albicans cells to adhere and to form
biofilms on catheter pieces in vitro. After C. albicans adhe-
sion on the catheters, a significantly lower BLI signal was
detected from catheters inoculated with bcr1−/−-ACTgLuc
compared with those inoculated with SC-ACTgLuc
(Fig. 5, panel A). This corresponds to the lower numbers
Fig. 5. In vitro and in vivo BLI of defective adhesion and biofilm formation.
A. Graphs of BLI signal intensity and cfu quantification of (defective) biofilm formation by bcr1−/−-ACTgLuc and SC-ACTgLuc C. albicans cells
in catheter pieces (n = 6).
B. In vivo BLI signal quantification (left graph) from biofilms formed by bcr1−/−-ACTgLuc and SC-ACTgLuc C. albicans cells on implanted
catheter pieces, after catheter implantation (90 min, n = 12 mice) and after 2 (n = 12 mice) and 6 days (n = 6 mice) of in vivo biofilm
development. The graph on the right represents cfu quantified from biofilms formed by bcr1−/−-ACTgLuc and SC-ACTgLuc C. albicans cells at
the time of implantation (90 min, n = 4 per strain) or explanted from mice after 2 and 6 days (n = 18 per strain).
C. In vivo BLI images from one representative (i.e. showing average BLI signal) mouse imaged at three different time points after catheter
implantation are shown (Error bars indicate SD of replicate samples; *P < 0.05, **P < 0.005, ***P < 0.0005).
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of bcr1−/− Candida cells compared with wt that were able
to attach onto the catheter, which is in agreement with
the known adhesion defect of this strain (Nobile et al.,
2006; Rˇ icˇicová et al., 2010). After 2 days and 6 days of
mature biofilm formation, significantly lower BLI signal
intensities were detected from catheter pieces inoculated
with bcr1−/−-ACTgLuc compared with the SC-ACTgLuc
strain (Fig. 5, panel A), indicating the inability of the bcr1
mutant strain to form normal biofilms. The lower BLI signal
intensities emanating from bcr1−/−-ACTgLuc-inoculated
catheters corresponded to significantly reduced numbers
of cfu recovered from these catheters compared with the
control strain, validating BLI as a technique to monitor
defective adhesion and biofilm formation of the bcr1−/−
C. albicans strain on catheters under in vitro conditions.
To evaluate the biofilm forming capability of bcr1−/−
mutant C. albicans under in vivo conditions with BLI, cath-
eters inoculated with ACTgLuc-expressing bcr1−/− and wt
strains were implanted on the back of mice (n = 12). All
mice were imaged with BLI after catheter implantation
(n = 12) and after 2 days (n = 12). After the 2 days’
imaging time point, half of the mice (n = 6) were sacrificed
for catheter explantation and ex vivo quantification of cfu.
At the 6 days’ imaging time point, the remaining half of
the group (n = 6) was imaged and sacrificed thereafter
for catheter explantation and validation of the imaging
results. Catheter pieces (n = 4 per strain) were handled in
parallel with the catheters for implantation and used for
quantification of cfu, to evaluate the adhesion properties
of the Candida strain at the time of implantation. In vivo
BLI revealed significantly lower BLI signal intensities for
the bcr1−/−-ACTgLuc-inoculated catheters compared with
SC-ACTgLuc-inoculated catheters, illustrating the ham-
pered adhesion properties of this strain. This was con-
firmed by the cfu retrieved from the catheters at the time
of implantation (Fig. 5, panels B and C). Also at the
following in vivo imaging time points (2 and 6 days), the
BLI signal intensity from bcr1−/−-ACTgLuc-inoculated
catheters was significantly lower than the signal from
ACTgLuc-expressing control biofilms, demonstrating the
inability of the bcr1−/−-strain to form normal biofilms under
in vivo conditions (Fig. 5, panels B and C). This was
clearly visualized for every individual animal (Fig. 5, panel
C). The imaging results were at all time points in agree-
ment with the amount of cfu quantified from the biofilms
(Fig. 5, panel B) and defective in vitro and in vivo biofilm
formation by the bcr1−/−-ACTgLuc-strain was confirmed by
SEM (data not shown) as shown before (Rˇ icˇicová et al.,
2010).
In the context of assessing adherence properties and
biofilm forming capabilities of a mutant Candida strain that
is potentially defective for biofilm formation, it becomes
relevant to evaluate the bioluminescence emitted by
biofilm cells versus planktonic cells that are not associ-
ated with a biofilm structure. In order to evaluate to what
extent planktonic cells that are not attached to mature
biofilm structures contribute to the overall in vivo BLI
signal, we collected the free floating cells from inside the
lumen of the explanted catheters and compared them with
the biofilm that remains adhered to the catheters. Com-
paring the BLI signal of the cells in the washing fluid with
the overall in vivo BLI signal emanating from biofilms
formed on implanted catheters (compare Fig. S3, panel B
with Fig. 5, panel B), the BLI signal intensity is at least one
order of magnitude lower, showing that the BLI signal of
planktonic cells not associated with the biofilm structure
form only a minor fraction and have only a marginal con-
tribution to the overall in vivo BLI signal. Interestingly, after
2 days of biofilm formation, a significantly lower BLI signal
intensity, close to background, was measured for bcr1−/−-
ACTgLuc-inoculated catheters, due to a large fraction of
catheters for which zero cfu of planktonic cells were
recovered from the catheter lumen (89% for bcr1−/−-
ACTgLuc-inoculated catheters versus 39% for ACTgLuc-
expressing control biofilms). This illustrates that the
overall in vivo BLI signal reflects the biomass associated
with the catheter, with a negligible contribution from loose
planktonic cells in the catheter lumen. Quantification of
the cfu corroborated the BLI results for the washing fluid,
confirming that BLI is a valid technique to conveniently
assess planktonic versus biofilm-associated cells on sub-
cutaneously implanted catheters in vivo.
Taken together, our data illustrate that BLI is a power-
ful technique to monitor and quantify the adhesion
between C. albicans strains and the substrate, as well as
further biofilm formation, both under in vitro and in vivo
conditions.
Discussion
We have demonstrated for the first time that biofilm for-
mation by C. albicans, the transition from yeast to hyphae
morphology during biofilm formation and defects in adher-
ence properties and biofilm formation by selective
mutants can be monitored longitudinally in individual
animals by using bioluminescence imaging. One of the
key challenges in Candida biofilm research is the devel-
opment of suitable in vivo models that account for host
factors at different infection sites and that allow to evalu-
ate the potential and efficacy of novel antifungal treatment
strategies (Nett and Andes, 2006). Several in vitro
C. albicans biofilm model systems are available to eluci-
date the architecture, developmental stages, cell pheno-
types and drug resistance of biofilms (Nett and Andes,
2006). However, these models cannot account for the
numerous host and infection-site variables that are impor-
tant during infections in humans. Recently, in vivo central
venous catheter (CVC) C. albicans biofilm models were
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developed in rabbits, rats and mice (Andes et al., 2004;
Schinabeck et al., 2004; Lazzell et al., 2009). Although
they are extremely valuable for C. albicans biofilm
research under in vivo conditions, these models have the
disadvantage of being technically demanding, exposing
the animals to a major surgical intervention and having
a very low throughput. Rˇ icˇicová et al. have addressed
this issue and developed a rat in vivo C. albicans foreign
body infection model in which small pieces of catheter
challenged with C. albicans cells are subcutaneously
implanted in rats (Rˇ icˇicová et al., 2010). This model can
produce similar biofilms as in the CVC models with the
major advantage that up to nine catheter fragments can
be implanted in one animal with only minor surgery.
Although this model cannot account for factors as shear
stress and nutrient flow as is observed in the blood
stream, the suitability of the model to evaluate the efficacy
of antifungal drugs on biofilm development was shown,
allowing more rapid screening under in vivo conditions
(Kucharíková et al., 2010; 2013; Bink et al., 2012).
Translating this rat biofilm model to mice further
improved the cost-efficiency of in vivo screening and
holds potential for biofilm research in different transgenic
mouse strains that would allow for studying different host
factors. Making these animal models compatible with BLI
reduces the costs and number of animals needed even
further. Moreover, the major advantage of BLI-compatible
animal models lies in that only non-invasive imaging has
the potential to provide dynamic information on the infec-
tion process and immune response in individual animals
(Hutchens and Luker, 2007). In the case of bacterial
pathogens, luminescent reporters based on the lux
operon can be used, which have the advantage that there
is no need for substrate addition as this is produced
intracellularly (Gahan, 2012). For eukaryotic cells, other
intracellularly expressed luciferases such as firefly,
Renilla and click beetle luciferases) are available and
commonly used (Badr and Tannous, 2011), but here bio-
luminescence relies on external substrate administration
and therefore, on sufficient intracellular substrate avail-
ability. The development of BLI for imaging fungal infec-
tions has to address some additional challenges,
including the fungal cell wall, which was found to be an
obstacle for the intracellular substrate availability for the
intracellularly located firefly luciferase (Doyle et al., 2006).
Engineering the naturally secreted Gaussia luciferase to
be located extracellularly partially solved the problem in
the sense that superficial C. albicans infections could suc-
cessfully be imaged with in vivo BLI upon topical applica-
tion of its substrate CTZ (Enjalbert et al., 2009). However,
BLI was not successful for imaging C. albicans infection
from deeper infection sites due to yet not fully understood
reasons (Enjalbert et al., 2009). Contributing factors might
be found in some of the disadvantages that are associ-
ated with the in vivo use of gLuc; namely the emission of
blue bioluminescence which is more absorbed and scat-
tered by the tissue than light with longer wavelengths, and
the rapid clearance of its substrate CTZ from the blood
(Zhao et al., 2004; Tannous et al., 2005).
The challenges of BLI to visualize fungal infections
were also illustrated by the work of Donat et al. in which a
bioluminescent Aspergillus fumigatus strain was devel-
oped using cell wall-exposed gLuc (Donat et al., 2012).
Their attempts to image pulmonary infection of this biolu-
minescent strain in vivo failed. When imaging cutaneous
infection, they did observe a bioluminescent signal but
could not establish a correlation between fungal load and
BLI signal intensity. The latter might be explained by the
high degree of instability through auto-oxidation of CTZ,
which resulted in a high background signal (Shimomura
et al., 1993; Tannous et al., 2005).
In our study, we also use extracellular gLuc, which
warrants better accessibility of the substrate and is a
prerequisite for a detectable bioluminescent signal in vivo,
circumventing restricted diffusion through the fungal cell
wall. Although the substrate CTZ – like any nutrient –
needs to diffuse through the extracellular matrix to reach
the gLuc expressed at the cell wall of the Candida
cells, our results show that these challenges can be
overcome and that BLI proves to be a sensitive tool pro-
viding dynamic information on biofilm development using
the extracellularly located gLuc reporter that was origi-
nally developed by the d’Enfert-group (Enjalbert et al.,
2009).
We have shown the feasibility of sensitive and dynamic
BLI of biofilms formed on foreign bodies in vitro. It has the
potential to be used as a rapid, easy and cost-effective
screening technique for studies of in vitro biofilm forma-
tion, validating interesting proteins of the pathogen
involved in biofilm formation as shown here for Bcr1 and
assessing morphogenesis and antifungal testing. The BLI
technique forms a valuable non-destructive alternative
next to other alternatives for quantitative analysis of in
vitro biofilm growth, e.g. cfu counting, XTT reduction
assay, crystal violet assay or other published techniques
such as the ATP bioluminescence assay (Nikawa et al.,
1996).
More importantly, we were able to show in vivo BLI
signal quantification from C. albicans biofilms developed
in vivo on catheters implanted on the back of mice. The
BLI signal intensity was in agreement with the amount of
cfu recovered from explanted biofilms for validation,
showing for the first time that BLI to non-invasively
monitor fungal biofilm formation in live animals is feasible.
Co-registering BLI and MR images adds information on
the exact position of the catheters and on tissue thickness
and composition between the catheter and the BLI
camera. However, prior knowledge of the exact catheter
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position from MRI does not have a significant influence
on the accuracy of BLI signal quantification in our model.
This brings BLI as a relatively cheap tool for imaging
and quantification of in vivo biofilm formation within the
reach of many labs. When translating the technology
towards other models of in vivo biofilm formation that
involve deeper implantation sites, we anticipate that co-
registration with MRI might become more important to
provide information on the exact catheter position, on the
nature of the surrounding tissue types or the presence of
bleedings or scar formation to potentially correct for dif-
ferences in light absorption and scattering properties.
When imaging in vitro and in vivo biofilms, one might
expect a limited delivery of substances, for example CTZ,
to the gLuc-expressing C. albicans cells inside the dense
extracellular matrix in fully developed biofilms. However,
studies looking at restricted penetration as a potential
factor leading to increased drug resistance of biofilms
have indicated that the matrix does not form a major
barrier to drug diffusion (Al-Fattani and Douglas, 2004),
although for some substances penetration can be delayed
(Mah and O’Toole, 2001). C. albicans itself possesses
different types of efflux pumps (Ramage et al., 2002), but
as gLuc is located extracellularly, these efflux pumps are
unlikely to be relevant for potentially limiting the substrate
availability for the bioluminescence reactions in this study.
The observed increased background BLI signal from
fully developed wt biofilms indicate that an increased
amount of biomass increases the chemiluminescence of
CTZ. A similar phenomenon of aspecific BLI signal from
wt C. albicans infection sites compared with non-infected
controls has been previously observed (Enjalbert et al.,
2009), but remains unexplained. For some biomolecules
like albumin and insulin it was shown that they catalyse
CTZ chemiluminescence (Vassel et al., 2012), but for
compounds that constitute biofilms, studies on their pos-
sible influence on CTZ chemiluminescence are currently
lacking. Nevertheless, this observation highlights the
importance of taking the necessary controls when
imaging bioluminescence using CTZ.
In the case of in vivo BLI of biofilms in implanted cath-
eters, the formation of fibrous scar tissue around the
catheters can be an additional factor in the relatively lower
specific BLI signal at later time points. This scar tissue has
an influence on slowing down the diffusion of CTZ
towards the catheters, which is reflected in an increased
time-to-peak of the BLI signal after CTZ administration
(data not shown). However, our MRI data did not indicate
excessive bleeding or scar formation in individual
animals.
Using a morphogenesis-dependent promoter, we
showed that hyphal growth during biofilm maturation can
be monitored with BLI in vitro and in live animals. The
change in specific BLI signal from hyphal cells was most
pronounced during the first stages of mature biofilm for-
mation, as most cells go through the transition from the
yeast to the hyphal cell stage (Blankenship and Mitchell,
2006). Once a mature biofilm is formed, the differences
between the specific hyphal BLI signal and the BLI signal
driven by the ACT1 promoter are less pronounced. This
might reflect the hyphal content of the biofilm at this
stage (Nett and Andes, 2006). In this context, it is of note
that the activity of the ACT1 promoter is not constant
throughout the different stages of biofilm formation
(Nailis et al., 2006). It would be of interest to add BLI
studies on morphogenesis of biofilms using a yeast cell
stage specific promoter for gLuc expression and/or
mutants defective in hyphae formation i.e. that do not
express the hyphal cell wall protein (Baillie and Douglas,
1999).
We also demonstrated that BLI can be used to monitor
the role of a gene involved in biofilm formation. By engi-
neering the bcr1−/− mutant C. albicans to be biolumines-
cent, we could visualize and quantify its hampered
substrate adherence and inability to form normal biofilms
in vitro and in vivo, which is a known effect of the double
BCR1 knockout in this strain (Nobile et al., 2006; Rˇ icˇicová
et al., 2010). BLI shows to be a powerful tool to dynami-
cally monitor the function of genes involved in biofilm
formation, thereby opening the door towards more rapid
and convenient screening and validation of genes of the
pathogen playing a role in biofilm formation and dynamic
follow-up of the interplay between pathogen and substrate
within the living host.
Conclusion & perspectives
We have demonstrated the feasibility of using BLI to non-
invasively and longitudinally monitor biofilm develop-
ment and morphogenesis in subcutaneously implanted
catheters in rodents. We expect this approach to be
readily translatable to other biofilm models such as the
CVC model as the intravenous (iv) catheter is located not
too deep under the skin and iv CTZ injection might result
in a favourable substrate delivery and reproducibility of
BLI results. Studies are underway to evaluate the feasi-
bility of BLI for in vivo biofilm research in the CVC model
that will enable to account for factors as shear stress and
nutrient flow on biofilm formation. The here described
multi-temporal non-invasive imaging tool for quantifying in
vitro and in vivo biofilm formation has the potential for
applications in the screening and validation of antifungal
drugs under in vivo conditions, for studying host–biofilm
interactions in different transgenic mouse models and for
studying the virulence of mutant C. albicans in this lumi-
nescent background, and hereby contribute to a better
understanding of the pathogenesis of yeast infections
during biofilm formation.
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Experimental procedures
Strains and culture media
Wild-type C. albicans SC5314, a clinical isolate with a success-
fully sequenced genome (Gillum et al., 1984) was used as
a control strain in these studies. This strain was engineered
to express C. albicans codon-optimized Gaussia princeps
luciferase (gLuc) at the cell wall, under the control of a consti-
tutive (actin, ACT1) and a hyphal growth phase-specific
(HWP1) promoter. SC5314 was transformed in the RPS1 locus
with the Clp10::Act1p-gLUC59 plasmid (Enjalbert et al., 2009),
kindly provided to us by Prof. C. d’Enfert, in which we replaced
the URA3 transformation marker with SAT1. Positive
transformants were identified by BLI and confirmed by PCR.
Two bioluminescent transformants (SKCA23-ACTgLuc and
SKCA43-ACTgLuc) that were normal regarding hyphal induc-
tion and growth (data not shown) were selected for both in vitro
and in vivo biofilm bioluminescence assays. These strains
express gLuc fused to the endogenous PGA59 gene under the
control of the ACT1 promoter. The results with both strains
were similar and all data presented in this paper were obtained
with SKCA23-ACTgLuc.
Similarly, we transformed the mutant C. albicans CJN702 -
bcr1/bcr1 (ura3Δ::λimm434/ura3Δ::λimm434 arg4::hisG/arg4::
hisG his1::hisG/his1::hisG::pHIS1 bcr1::ARG4/bcr1::URA3)
(Nobile and Mitchell, 2005) with the Clp10::Act1p-gLUC59
plasmid, resulting in the bioluminescent strain further referred to
as bcr1−/−-ACTgLuc.
Also used in this study were strains CEC971 (HWP1p-PGA59-
gLUC, morphogenesis-dependent expressing of gLuc, further
referred to as CEC971-HWPgLuc), CEC988 (ACT1p-PGA59-
gLUC, further referred to as CEC988-ACTgLuc) and DAY185 (wt
control), kindly provided to us by Prof. C. d’Enfert (Enjalbert et al.,
2009).
In vitro biofilm formation
Strains were grown overnight on YPD plates at 37°C, washed
and resuspended in PBS. The cells were counted to prepare a
C. albicans cell suspension in RPMI medium (RPMI-1640,
R6504, Sigma-Aldrich, Diegem, Belgium; with L-glutamine and
without sodium carbonate buffered with MOPS, pH 7.0). To study
biofilm formation in vitro, sterile 96-well (24-well) polystyrene cell
culture plates were inoculated by adding 100 μl (200 μl) per well
of a 1 × 107 cells ml−1 C. albicans cell suspension in RPMI. The
C. albicans cells were allowed to adhere to the bottom of the
wells by incubating the plate for 90 min at 37°C. After washing
twice with PBS, attached cells were submerged in 200 μl (96-well
plate) or 1 ml (24-well plate) of fresh RPMI medium and the plate
was again incubated at 37°C for the duration of the experiment to
allow formation of mature biofilms. To study biofilm formation on
the inside of a catheter in vitro, polyurethane triple-lumen intra-
venous catheters (2.4 mm diameter, Certofix Trio S730, BBraun,
Diegem, Belgium) were cut into 1 cm long fragments and incu-
bated overnight with FBS (F7524, Sigma) at 37°C. A C. albicans
cell suspension of 5 × 104 cells ml−1 was added to the catheters
placed in a 24-well plate and incubated for 90 min at 37°C for
adhesion. Catheters were washed twice with PBS, transferred to
a clean plate and submerged in 1 ml of fresh RPMI medium and
incubated at 37°C for the duration of the experiment.
In vitro BLI
To obtain in vitro bioluminescence measurements, the plates
containing cell suspensions, biofilms formed on the bottom of cell
culture plates or biofilms formed inside catheter pieces were
placed in a BLI-camera (IVIS 100, Perkin-Elmer, Waltham, MA,
USA). For all in vitro experiments, a native coelenterazine (CTZ;
Nanolight Technologies, Pinetop, AZ, USA) working solution in
PBS was prepared freshly from a 5 mg ml−1 stock solution in
acidified ethanol, prepared and stored at −80°C according to the
manufacturer’s instructions. After acquisition of a background
image, CTZ was added to the wells at a final concentration of
6 μM. Subsequent frames were acquired with a 5–20 s exposure
time depending on the signal intensity, at medium binning. The
BLI signal was quantified using Living Image software (version
2.50.1, provided by the manufacturer) and reported as photon
flux per second (p s−1) for a given ROI of fixed size covering the
well or catheter (for more details, see Vande Velde et al., 2013).
In vitro BLI data were normalized to the background signal from
CTZ alone unless stated otherwise.
Animals
Female, 8-week-old Balb/C mice and Sprague-Dawley rats of
200 g (Janvier, Le Genest Saint-Isle, France) were used for in
vivo biofilm studies. The animals were kept in individually venti-
lated filter top cages with free access to standard food and water
ad libitum. All animals were immunosuppressed starting 24 h
before and during the entire experiment by adding dexametha-
sone (0.4 mg l−1; Fagron SAS, Paris, France) to their drinking
water. Ampicillin (ampicillin sodium powder 0.5 g l−1; Duchefa
Biochemie, Haarlem, the Netherlands) was also added to the
water to prevent possible bacterial infections. All aspects of
animal experiments were carried out in compliance with national
and European regulations and were approved by the animal
ethics committee of the KU Leuven.
In vivo biofilm model
Catheter segments of 1 cm length were incubated overnight in
FBS (100%) at 37°C. Serum-coated catheters were incubated for
90 min at 37°C in a 1 ml C. albicans cell suspension (5 × 104
cells ml−1 prepared in RPMI). After incubation, catheters were
washed twice with PBS before implanting them under the skin of
mice or rats as described previously, with minor adaptations
(Rˇ icˇicová et al., 2010). In brief, general anesthesia was per-
formed by intraperitoneal injection of a mixture of ketamine
(Ketamine1000®; Pfizer, Puurs, Belgium) and medetomidine
(Domitor®; Pfizer) (45 mg kg−1 ketamine and 0.6 mg kg−1
medetomidine for mice, 60 mg kg−1 ketamine and 0.4 mg kg−1
medetomidine for rat) and local anaesthesia by application of
xylocaine gel (2%, AstraZeneca, Zoetermeer, the Netherlands)
on the skin. The lower back of the animals was shaved and
disinfected with iodine isopropanol (1%). A small incision was
made and the subcutis was carefully dissected to create two (for
mice) or three (for rats) subcutaneous tunnels. In each tunnel,
three catheter pieces were inserted. In total, six (for mice) or nine
(for rats) catheter fragments were implanted (see Vande Velde
et al., 2013 for more details). The incision was closed with sur-
gical staples or sutured with surgical thread and disinfected.
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Anesthesia was reversed with intraperitoneal injection of
atipamezole [Antisedan® (Pfizer), 0.5 mg kg−1 for mice, 1 mg kg−1
for rats]. For catheter explantation, the animals were euthanized
by cervical dislocation. The skin was disinfected with 0.5%
chlorhexidine in 70% alcohol; catheter fragments were removed
from under the subcutaneous tissue and washed twice with PBS
for further quantification of biomass.
Magnetic resonance imaging (MRI)
MR images were acquired on a 9.4 Tesla Biospec small animal
scanner (Bruker Biospin, Ettlingen, Germany) equipped with an
actively shielded gradient set of 600 mT m−1 and in combination
with a 7.5 cm quadrature coil (Bruker Biospin) for radio-frequency
irradiation and detection. The mice were anesthetized by inhala-
tion of 3% isoflurane (Abbott Laboratories, Queenborough, UK)
for induction and 1.5% isoflurane for maintenance in 100% O2 at
a flow rate of 600 ml min−1. Breathing rate and body temperature
were continuously monitored using an MR compatible physiologi-
cal monitoring system (SAII, Stony Brook, NY, USA). Localizer
images were acquired first and used for proper positioning and
orientation of subsequently acquired images. Whole-body
images were acquired with an in-plane resolution of 200*200 μm2
using a 2D spin echo sequence (RARE) with the following param-
eters: RARE factor = 8, TEeff = 15.9 ms, TR = 6000 ms, 2 aver-
ages, matrix = 200*400, FOV = 40*80 mm2, 50 continuous slices
of 500 μm thickness; resulting in a total scanning time of
∼ 12 min. MR images were processed using Paravision 5.1 soft-
ware (Bruker Biospin) and exported in Dicom format. For
co-registration of BLI and MR images, the photographic image
from BLI was overlaid with the whole-body MR image using
in-house developed software (Carlon et al., 2010). Hereby, limb
position and size were used as reference points.
In vivo BLI
The animals were anesthetized using a gas mixture of isoflurane
in oxygen (1.5–2% for mice and 2–3% for rats) and imaged in the
IVIS 100 system. Before every in vivo imaging session, the
1.2 mM CTZ working solution was prepared freshly from a
5 mg ml−1 stock solution by dilution in PBS. A volume of 100 μl
CTZ was topically applied simultaneously to each catheter trio by
subcutaneous injection in each tunnel. Subsequently, the animal
was placed in the BLI camera and consecutive frames were
acquired with a field of view of 10 cm. Consecutive scans with
acquisition time of 20–60 s (depending on the signal intensity)
were acquired starting immediately (i.e. within 10 s) after CTZ
administration until maximum signal intensity was reached. The
BLI signal of each catheter trio was quantified using Living Image
software and reported as photon flux per second (p s−1) for a
rectangular ROI of 95 cm2 placed over each catheter trio. Back-
ground BLI signal was measured by using the same ROI after
injecting CTZ subcutaneously on the upper back of the mouse
(no catheters implanted). All in vivo experiments were repeated
twice with similar results.
Biofilm quantification
The metabolic activity of the biofilm forming cells was quantified
by using the XTT reduction assay, Biofilms formed on 96-well
plates were washed twice with PBS and 100 μl of XTT-solution
(1 mg ml−1) supplemented with menadion (1 μM) was added in
the absence of light. Plates were subsequently incubated at 37°C
for 1–3 h and the colorimetric changes were measured with a
spectrophotometer (SPECTRAmax plus 384, Molecular Devices,
Sunnyvale, CA, USA) at 490 nm.
For fungal burden assessment by cfu quantification, biofilms
formed on cell culture plates, in in vitro evaluated catheters and
explanted catheters were washed twice with PBS, sonicated for
10 min at 40 000 Hz in a water bath sonicator (Branson 2210)
and vortexed for 30 s in PBS. Original samples, 1:10 and 1:100
dilutions were plated on YPD agar in duplicate. Cfu were counted
after incubating the plates for 2 days at 37°C.
Statistics
All reported experiments were repeated twice and analysed
separately, yielding consistent results. Data were expressed as
mean ± standard deviation (SD). Significance tests were per-
formed using unpaired t-test and ANOVA with Tukey post-test
with P-values of < 0.05 considered significant, represented as
follows: *P < 0.05, **P < 0.005, ***P < 0.0005. For statistics and
representation of the results we used Microsoft Office Excel 2007
(Microsoft Corporation, Seattle, WA, USA) and GraphPad Prism
5 (GraphPad Software, La Jolla, CA, USA).
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Fig. S1. Phosphorescence of different common catheter types.
Three different brands of triple lumen catheters (Arrow, Edwards
Swan-Ganz, BBraun Certofix) were cut in 1 cm long pieces and
placed in Petri dishes for image acquisition with the BLI camera.
Panel A: luminescence image acquired after exposing the cath-
eters to light by opening-closing of the scanner door, showing
phosphorescence signal emitted by the triple-lumen Swan-Ganz
and Arrow catheter pieces, while no phosphorescence signal was
detected for the Certofix catheter pieces. Panel B is the same
image as in panel A, showing the overlaid ROIs used for quan-
tification of the background and phosphorescence signals as
plotted in Fig. 1A.
Fig. S2. BLI of yeast-to-hyphal cell ratio. HWPgLuc-expressing
C. albicans cells were cultured either to be in the yeast cell from
(in YPD medium) or in the hyphal cell form (YP medium contain-
ing 10% fetal bovine serum). Candida yeast and/or hyphal cell
suspensions of 1 × 107 cells ml−1 were plated in 24-well plates,
in a total volume of 1 ml medium, imaged with BLI in triplicate
series as follows: HWPgLuc-expressing C. albicans hyphal/yeast
cells in ratios (%): 100/0–80/20–60/40–40–60–20/80–0/100. The
graph represents the BLI results and linear regression line
(R2 = 0.9559), showing near-perfect correlation of the biolumi-
nescence signal intensity with the percentage hyphal content in
the sample. Error bars are StDev of triplicate samples.
Fig. S3. BLI of planktonic bcr1−/−-ACTgLuc cells.
A. BLI of 10-fold dilutions of bcr1−/−-ACTgLuc and SC5314-
ACTgLuc (wt control) C. albicans cells, and CTZ alone (n = 3).
The BLI-signal emitted from bcr1−/−-ACTgLuc and SC5314-
ACTgLuc C. albicans was found to be equal and correlated
strongly with the number of cells. (R2 (bcr1−/−-ACTgLuc) = 0.957,
R2 (SC5314-ACTgLuc) = 0.999).
B. BLI signal (left graph) and cfu (right graph) quantified from
the planktonic cells collected from the lumen of explanted cath-
eters at different time points of biofilm formation by bcr1−/−-
ACTgLuc and SC-ACTgLuc C. albicans strains. The means of
triplicate samples per catheter (n = 18) were plot. Error bars
indicate SD of replicate samples; *P < 0.05, **P < 0.005,
***P < 0.0005).
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